164 related articles for article (PubMed ID: 24973039)
1. [¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins.
Mena E; Owenius R; Turkbey B; Sherry R; Bratslavsky G; Macholl S; Miller MP; Somer EJ; Lindenberg L; Adler S; Shih J; Choyke P; Kurdziel K
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1879-88. PubMed ID: 24973039
[TBL] [Abstract][Full Text] [Related]
2. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.
Battle MR; Goggi JL; Allen L; Barnett J; Morrison MS
J Nucl Med; 2011 Mar; 52(3):424-30. PubMed ID: 21321268
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Reproducibility of 18F-Fluciclatide PET Imaging in Subjects with Solid Tumors.
Sharma R; Kallur KG; Ryu JS; Parameswaran RV; Lindman H; Avril N; Gleeson FV; Lee JD; Lee KH; O'Doherty MJ; Groves AM; Miller MP; Somer EJ; Coombes CR; Aboagye EO
J Nucl Med; 2015 Dec; 56(12):1855-61. PubMed ID: 26383153
[TBL] [Abstract][Full Text] [Related]
4. PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time?
Beer AJ; Schwaiger M
J Nucl Med; 2011 Mar; 52(3):335-7. PubMed ID: 21321266
[No Abstract] [Full Text] [Related]
5. In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis.
Jenkins WS; Vesey AT; Vickers A; Neale A; Moles C; Connell M; Joshi NV; Lucatelli C; Fletcher AM; Spratt JC; Mirsadraee S; van Beek EJ; Rudd JH; Newby DE; Dweck MR
Heart; 2019 Dec; 105(24):1868-1875. PubMed ID: 31422361
[TBL] [Abstract][Full Text] [Related]
6. Cardiac α
Jenkins WS; Vesey AT; Stirrat C; Connell M; Lucatelli C; Neale A; Moles C; Vickers A; Fletcher A; Pawade T; Wilson I; Rudd JH; van Beek EJ; Mirsadraee S; Dweck MR; Newby DE
Heart; 2017 Apr; 103(8):607-615. PubMed ID: 27927700
[TBL] [Abstract][Full Text] [Related]
7. Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [(18)F]fluciclatide kinetics and [ (15)O]H 2O PET.
Kenny LM; Tomasi G; Turkheimer F; Larkin J; Gore M; Brock CS; Mangar S; Aboagye EO
EJNMMI Res; 2014 Dec; 4(1):30. PubMed ID: 26055935
[TBL] [Abstract][Full Text] [Related]
8. 18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology.
Withofs N; Signolle N; Somja J; Lovinfosse P; Nzaramba EM; Mievis F; Giacomelli F; Waltregny D; Cataldo D; Gambhir SS; Hustinx R
J Nucl Med; 2015 Mar; 56(3):361-4. PubMed ID: 25655629
[TBL] [Abstract][Full Text] [Related]
9. Complementary, Selective PET Imaging of Integrin Subtypes α5β1 and αvβ3 Using 68Ga-Aquibeprin and 68Ga-Avebetrin.
Notni J; Steiger K; Hoffmann F; Reich D; Kapp TG; Rechenmacher F; Neubauer S; Kessler H; Wester HJ
J Nucl Med; 2016 Mar; 57(3):460-6. PubMed ID: 26635338
[TBL] [Abstract][Full Text] [Related]
10. [
Sharma R; Valls PO; Inglese M; Dubash S; Chen M; Gabra H; Montes A; Challapalli A; Arshad M; Tharakan G; Chambers E; Cole T; Lozano-Kuehne JP; Barwick TD; Aboagye EO
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1239-1251. PubMed ID: 31754793
[TBL] [Abstract][Full Text] [Related]
11. A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients.
Gao S; Wu H; Li W; Zhao S; Teng X; Lu H; Hu X; Wang S; Yu J; Yuan S
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2029-37. PubMed ID: 26153145
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.
Kenny LM; Coombes RC; Oulie I; Contractor KB; Miller M; Spinks TJ; McParland B; Cohen PS; Hui AM; Palmieri C; Osman S; Glaser M; Turton D; Al-Nahhas A; Aboagye EO
J Nucl Med; 2008 Jun; 49(6):879-86. PubMed ID: 18483090
[TBL] [Abstract][Full Text] [Related]
13. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
14. [(18)F]FPRGD2 PET/CT imaging of integrin αvβ3 levels in patients with locally advanced rectal carcinoma.
Withofs N; Martinive P; Vanderick J; Bletard N; Scagnol I; Mievis F; Giacomelli F; Coucke P; Delvenne P; Cataldo D; Gambhir SS; Hustinx R
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):654-62. PubMed ID: 26490751
[TBL] [Abstract][Full Text] [Related]
15. Expression of integrins αvβ3 and αvβ5 and their ligands in primary and secondary central nervous system neoplasms.
Mittelbronn M; Warth A; Meyermann R; Goodman S; Weller M
Histol Histopathol; 2013 Jun; 28(6):749-58. PubMed ID: 23238957
[TBL] [Abstract][Full Text] [Related]
16. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
[TBL] [Abstract][Full Text] [Related]
17. Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis.
Bretschi M; Cheng C; Witt H; Dimitrakopoulou-Strauss A; Strauss LG; Semmler W; Bäuerle T
J Cancer Res Clin Oncol; 2013 Apr; 139(4):573-83. PubMed ID: 23229276
[TBL] [Abstract][Full Text] [Related]
18. PET/CT imaging of integrin αvβ3 expression in human carotid atherosclerosis.
Beer AJ; Pelisek J; Heider P; Saraste A; Reeps C; Metz S; Seidl S; Kessler H; Wester HJ; Eckstein HH; Schwaiger M
JACC Cardiovasc Imaging; 2014 Feb; 7(2):178-87. PubMed ID: 24412187
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
